Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Cyclically Adjusted Revenue per Share: ¥4.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600613 Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
53 GF Score
Price ¥4.70
GF Value ¥5.42
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted Revenue per Share?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 -3.29% 53 Cyclically Adjusted Revenue per Share is ¥4.02 as of Mar. 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 53/100 and a GF Value™ of ¥5.42 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shanghai Shenqi Pharmaceutical Investment Management Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.657. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Shanghai Shenqi Pharmaceutical Investment Management Co's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shanghai Shenqi Pharmaceutical Investment Management Co was 35.30% per year. The lowest was 1.80% per year. And the median was 16.60% per year.

As of today (2026-07-25), Shanghai Shenqi Pharmaceutical Investment Management Co's current stock price is ¥4.70. Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥4.02. Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted PS Ratio of today is 1.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Shenqi Pharmaceutical Investment Management Co was 10.94. The lowest was 1.11. And the median was 1.99.


Shanghai Shenqi Pharmaceutical Investment Management Co  (SHSE:600613) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.70/4.02
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Shenqi Pharmaceutical Investment Management Co was 10.94. The lowest was 1.11. And the median was 1.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted Revenue per Share Related Terms


Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted Revenue per Share Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 3.78 3.95 4.01 3.99

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 4.03 4.05 3.99 4.02

SHSE:600613 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600613
53GF Score
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Shenqi Pharmaceutical Investment Management Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shanghai Shenqi Pharmaceutical Investment Management Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.657/116.3033*116.3033
=0.657

Current CPI (Mar. 2026) = 116.3033.

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.754 101.400 0.865
201609 0.585 102.400 0.664
201612 1.210 102.600 1.372
201703 0.578 103.200 0.651
201706 0.796 103.100 0.898
201709 0.916 104.100 1.023
201712 1.073 104.500 1.194
201803 0.686 105.300 0.758
201806 0.911 104.900 1.010
201809 0.711 106.600 0.776
201812 1.109 106.500 1.211
201903 0.719 107.700 0.776
201906 1.087 107.700 1.174
201909 1.006 109.800 1.066
201912 1.127 111.200 1.179
202003 0.791 112.300 0.819
202006 0.960 110.400 1.011
202009 0.922 111.700 0.960
202012 0.980 111.500 1.022
202103 1.014 112.662 1.047
202106 1.068 111.769 1.111
202109 1.137 112.215 1.178
202112 1.088 113.108 1.119
202203 1.003 114.335 1.020
202206 1.281 114.558 1.301
202209 0.854 115.339 0.861
202212 1.367 115.116 1.381
202303 0.980 115.116 0.990
202306 1.106 114.558 1.123
202309 1.029 115.339 1.038
202312 1.487 114.781 1.507
202403 0.960 115.227 0.969
202406 1.111 114.781 1.126
202409 0.842 115.785 0.846
202412 0.840 114.893 0.850
202503 0.960 115.116 0.970
202506 0.810 114.907 0.820
202509 0.749 115.471 0.754
202512 1.090 115.832 1.094
202603 0.657 116.303 0.657

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥4.02 mean?
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Cyclically Adjusted Revenue per Share of ¥4.02 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted Revenue per Share too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current Cyclically Adjusted Revenue per Share is ¥4.02. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Shanghai Shenqi Pharmaceutical Investment Management Co's Cyclically Adjusted Revenue per Share of ¥4.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Cyclically Adjusted Revenue per Share is ¥4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.42, compared to a current price of ¥4.70 — trading 13.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥4.02. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Cyclically Adjusted Revenue per Share is ¥4.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued. The current stock price of ¥4.70 is trading 13.3% below its estimated GF Value™ of ¥5.42. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.

Key valuation signals for SHSE:600613:

  • Cyclically Adjusted Revenue per Share: ¥4.02
  • GF Value™: ¥5.42 vs. price of ¥4.70 (13.3% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Shenqi Pharmaceutical Investment Management Co Business Description

Other Exchanges 900904:China
Address 128 Weihai Road, Room 613, Changfa Building, Shanghai, CHN, 200003
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is mainly engaged in pharmaceutical production and distribution in China.
53GF Score

Get the complete analysis for SHSE:600613

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.70
Price
¥5.42
GF Value